Passage Bio Inc Ordinary Shares PASG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PASG is a good fit for your portfolio.
News
-
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
-
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
-
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
-
Passage Bio to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $1.28
- Day Range
- $1.27–1.34
- 52-Week Range
- $0.58–1.79
- Bid/Ask
- $1.30 / $1.33
- Market Cap
- $80.71 Mil
- Volume/Avg
- 36,628 / 330,957
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 85
- Website
- https://www.passagebio.com
Comparables
Valuation
Metric
|
PASG
|
EWTX
|
PLRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.75 | 3.08 | 1.95 |
Price/Sales | — | — | 3,406.41 |
Price/Cash Flow | — | — | — |
Price/Earnings
PASG
EWTX
PLRX
Financial Strength
Metric
|
PASG
|
EWTX
|
PLRX
|
---|---|---|---|
Quick Ratio | 8.14 | 36.49 | 15.95 |
Current Ratio | 8.43 | 37.08 | 16.12 |
Interest Coverage | — | — | −138.69 |
Quick Ratio
PASG
EWTX
PLRX
Profitability
Metric
|
PASG
|
EWTX
|
PLRX
|
---|---|---|---|
Return on Assets (Normalized) | −39.96% | −23.18% | −23.39% |
Return on Equity (Normalized) | −52.26% | −24.45% | −25.61% |
Return on Invested Capital (Normalized) | −43.53% | −28.92% | −29.08% |
Return on Assets
PASG
EWTX
PLRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cknrsvkh | Gkxg | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Byqxbdqc | Mmfxkym | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bqbftqy | Bvmsgy | $107.8 Bil | |
MRNA
| Moderna Inc | Hbnwdlvzl | Xblk | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Tjbdxfvcb | Lkcg | $22.2 Bil | |
ARGX
| argenx SE ADR | Txhltkm | Bny | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gcbdklb | Mczpg | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rdzhmkvqk | Zhqpf | $15.1 Bil | |
INCY
| Incyte Corp | Lbtyhkx | Hvzsrd | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Thjdgdgnlh | Bphfjy | $12.7 Bil |